Dynavax Technologies Corporation
Dynavax Technologies — Proxy Contest (May 2025)
83 slides from Dynavax Technologies's proxy contest presentation, May 6, 2025
Slide 1: The Path to Creating and Preserving Value at Dynavax
REFQCUS DYN@VAX The Path to Creating and Preserving Value at Dynavax May 2025 Presented by rHhek 6) CAPITALS
Slide 2: Legal Disclaimer
Legal Disclaimer eee ee ete So ea ane Se Ne Paes ae inset nce Sa Perit ree hanya eed ees ede mgd Sco a sespasbstoatd maplaseoueamiankoon a Me or me on Peck ow rs Lod date vied herein hove een derived or cbtcined fom publ lings including flings mode site he Secuttes end Exehenge Commision Urata iniod
Slide 3: Executive Summary
Executive Summary The Board's High-Risk Strategy and Poor Allocation of Capital Has Failed to Deliver for Shareholders Table of Te Coser Chang nthe OVA Boareroom Contents Sir Selon hapecsntandiaveion Aligned Voices in the Boardroom ) Appendix
Slide 4: About Deep Track Capital
About Deep Track Capital Deep Track Capital is one of the largest shareholders of Dynavax Technologies Corporation, with ownership of approximately 14.5% of the Company's outstanding shares Long-term: The senior members of Deep Track first purchased shares of Dynavax in a financing nearly 15 years a
Slide 5: About Dynavax Technologies
About Dynavax Technologies Company Snapshot Dynavox i one ofa select few slo mid-cap biopharmaceucal companies thot have succesful developed ond commercialized o veecne. The Company her one reverue-generting DYNAVAX commer + HEPLISAV-B® vaccine (Hepat + Ticker Symbol: VAX) B Vaccine (Recombinant), A
Slide 6: I. Executive Summary
BYNOVAX |. Executive Summary
Slide 7: Great Product — Bad Return: Dynavax's Perplexing Value-Creation Gap
Great Product — Bad Return: Dynavax’s Perplexing Value-Creation Gap ht Line for Four While TSR Has Been Decimated Consecutive Years. +332% 248mm REFOCUS 7 DYNOVAX
Slide 8: Executive Summary
Executive Summary + Heplisoy, 0 B voccing, i the ‘Company's crown jewel wisere Hep rtcal commercializtion point, but morket shore growth hos stalled ot ~ Aah + The Board ot DVAX, since the 2021 opment veel the Oynever hes 7 Requires Board Change to Refocus DVAX decisions thot have the potentiol to p
Slide 9: Heplisav is Dynavax's Unrivaled Growth Engine
Heplisav is Dynavax’s Unrivaled Growth Engine G@ Enduring and expanding demand ) Hepatitis Bis @ viral infection thot can lead to cirthosis, liver concer, and liver feilure. Once infected, there is no cure for hepatitis B. Although hepatitis B vaccination has been recommended for infants since 1991,
Slide 10: The DVAX Board is Pursuing a Counterproductive Diversification Strategy
The DVAX Board is Pursuing a Counterproductive Diversification Strategy + Vaccine development is noon difficult ond incredibly capitol intensive. © Adlon to expense, shareholders are concerned the current Board we te ralovart ail of ‘experience needed to successfully oversee @ vaccine development pr
Slide 11: Quixotic Search for a Vaccine Asset is Impacting the Heplisav Opportunity
Quixotic Search for a Vaccine Asset is Impacting the Heplisav Opportunity The deal search directs scarce management attention away from the obvious strategic priority — Heplisay growth + Hej © wholly owned osset positioned for many years of growth ond Heplisov Market Share! centinyed cosh geneetion
Slide 12: The Board is Hoarding Excess Cash Instead of Maximizing Value
The Board is Hoarding Excess Cash Instead of ‘imizing Value for We fear that this “war chest” of capital will be used to overpay for a value-destructive transaction *+ Cosh has grown to half of DVAX’s market cop. Estimated Contribution to Market Cap’ (© This dilutes shareholder exposure to the Compa
Slide 13: Dynavax's Cash Position is an Outlier
Dynavax’s Cash Position is an Outlier [ DVAX has the highest cash to market cap ratio among profitable biotech midcaps 52 ovMc Cash / Market Cap" 50% o 1 ' ' ' t ' t ' ' ' t 1 ' t ' t ' ' 1 t ' ' REFQCUS 13 DYNOVAX
Slide 14: Persistent Underperformance Reflects Shareholder Concerns
Persistent Underperformance Reflects Shareholder Concerns TSR reveals that Heplisay revenue growth is not enough to allay investor concerns * Heplioy soles grew more than fourfold from 2021 to 2024, and coment forecatsore srong, but DVAX TSR over the tenure of Chairman Scott My 0 REE ‘epproximately
Slide 15: Spotlight: Key Events Driving Total Shareholder Return
Spotlight: Key Events Driving Total Shareholder Return Three pivot points that drove divergence from the Nasdaq Biotechnology Index: + Odt. 21, 2021: Scott Myers appointed Choir, over next 30 days DVAX -13.5% vs. NBI-3.1%. + Aug. 4, 2022: Dis ‘PG pl over next 30 days VAX -18.7% vs. NBI -5.9% 1 iti i
Slide 16: Valuation Falls Below a Key Industry Benchmark
Valuation Falls Below a Key Industry Benchmark Investors are losing patience Enterprise Value / TTM Heplisav Sales The median EV / TTM Sales ratio of all liquid, US, jechnology companies that have revenve is Last year, DVAX shares fell below the median, reflecting investor frustration with slowing H
Slide 17: How We Got Here
How We Got Here ‘Apr 2010 (Oct 2021 ‘Apr 2022 0c 2024 Nov 2024 ‘Woee fis pucbose shore of Boord ond lees Chir xg ga ort 139 Oynovoe time a 2022 cempeny erences ecco sotenent Conpony edops pation it | | $200 sare repurese OvAKieer “S18 of hepa B wotcain for indcavien ence by FA toval jor aes Hough He
Slide 18: Deep Track's Efforts to Reach a Constructive Solution Have Been Rebuffed
Deep Track’s Efforts to Reach a Constructive Solution Have Been Rebuffed We have attempted to compromise but the Board has not changed its position ~ rem shareholder representative join as a director ing steadfastly opposed to having a + vax : 11, end od it ange for Deep apport 2027 + beep ine-membe
Slide 19: Deep Track's Efforts to Reach a Constructive Solution Have Been Rebuffed (cont.)
Deep Track’s Efforts to Reach a Constructive Solution Have Been Rebuffed (cont.) /e have attempted to compromise but the Board has not changed its position ~ rem shareholder representative join as a director ing steadfastly opposed to having a + Deep Trock prope: Erkmen ond, ‘ebolance the Boord’s cl
Slide 20: Dynavax's TSR Outperformance Claim is Disingenuous
Dynavax’s TSR Outperformance Claim is Disingenuous Cites a never-before- lentified “pivot” in March 2020 and says members created value without even being on the Board + On April 29, 2025, Dynavox mailed a letter to shareholders asserting that, since Dynavox’s “pivot” on or around March 31, 2020, th
Slide 21: Unbalanced Staggered Board Means Change at the 2025 AGM is Critical
Unbalanced Staggered Board Means Change at the 2025 AGM is Cri Pincers enthetaot | 2025 ei) @ Og This is a critical juncture in the oe staggered Board cycle. Next year, only one Independent “ 2 a € see 2027 ees fe ton Shoreholders connot offord to “give the Board another year" to sit on cash and con
Slide 22: We are Seeking to Remove Four Incumbent Directors
We are Seeking to Remove Four Incumbent Directors a — Brent MacGregor Scott Myers Lauren Silvernail Elaine Sun rate See 2020 (Chor Sine 2021 Dre Sen 2025, eat Se 2021 x Presided over -91% TSR as x Presided over 43% TSRas x Added to Board as part of x Member of Audit CEO of Medi Chair of the DVAX Boa
Slide 23: Michael Mullette
Michael Mullette een fc executive finonciol officer ond officer experience, tol morket Industry, would bring Lnderstonding of business risks leedership end humon copitol other derived from his various management skills, ineloding componies. coctvity REFOCUS eesnyouttnd
Slide 24: Elect Deep Track's highly qualified nominees
by electing Deep Track’s highly qualified nominees who core not fied to the Company's current strategy parrasieoioliipe et value-maximizing itegy in the boardroom € ‘Sharpen criteri a ‘Add independent and shareholder-aligned search for external assets Ensure consistent allocation of key resources to
Slide 25: II. The Board's High-Risk Strategy and Poor Allocation of Capital Has Failed to Deliver
BYNOVAX Il. The Board’s High-Risk Strategy and Poor Allocation of Capital Has Failed to Deliver for Shareholders
Slide 26: DVAX is Hoarding Cash While Heplisav Delivers De-Risked Double-Digit Returns
DVAX is Hoarding Cash While Heplisav Delivers De-Risked Double-Digit Returns vaccine poses signficont ris ies, for which D) 7 th the exception of Heplisav's delayed-but-eventual success, every other DVAX effort at axset development has been fr + DVAX was able to capi revenue spike (2020-22). ize on
Slide 27: DVAX Underestimates the Challenges of Vaccine Sales and Development
DVAX Underestimates the Challenges of Vaccine Sales and Development + Voccine development is notoriously difficult and incredibly capital intensive. isease prevention (vs. disease treatment) means there is almost no level of acceptable risk to subjects; even incredibly rare i de effects an result in
Slide 28: The Dynavax Scorecard
The Dynavax Scorecard DVAX Board has failed to oversee a number of key init Success Growing >25% y/y, with long-term guidance SroulBep tay oles Vv for >60% share of a >$900M market Dialysis label expansion Rejected by FDA in May 2024 Develop Tdap candidate Killed by management in Nov 2024 Next reado
Slide 29: The Board Has Already Seen All of the Few Viable Assets for Sale
The Board Has Already Seen All of the Few Viable Assets for Sale Pre-Commercial Vaccine Programs at Small Companies, by Di all Companies, by Disease * Many of he 33 pos-Phase | vaccine programs ot smal compos reer liniel sk ical, iterati of voec ne interesting dota don't come along very often. + We
Slide 30: Heplisav's Success is Rarefied—and Unlikely to be Replicated
Heplisav’s Success is Rarefied—and Unlikely to be Replicated by Dynavax Only four SMID Bi meaningful commercial success techs other than DVAX have secured FDA approval for vaccines in the last decade - only one of those had VAIN and EBS generated minimal soles with their vaccines. — _ VBIV went bank
Slide 31: The Majority of Vaccines Are Deployed By Large Vaccine Makers
The Majority of Vaccines Are Deployed By Large Vaccine Makers Dynavax is highly unlikely to find another asset with Heplisav's revenue potential and competitive barriers ‘Approvel Date Sponsor Brand Produc Indication 14,2025 GS Penne A a 17,2024 mK ‘CAPVAKE Poeumozoecl 1SolentCenjugote Voeine ‘Strep
Slide 32: Board's Lack of Vaccine Development Experience
Board’s Lack of Vaccine Development Experience Dynavax’s nominees only know the good times Heplisay Original ; Studies on (2006-2011) Addressing Deficiencies (2013-2017) None of th ctors up for elect ssociation or REFOCUS DYNOVAX
Slide 33: Heplisav's Delayed Approval Process Does Not Inspire Confidence
Heplisav’s Delayed Approval Process Does Not Inspire Confidence The Company spent over five years getting Heplisay approved - the standard timeline is 10 months 2006 ~ 2011: DVAX conducted « pair of registrational Phose 3 trials. 4/16/2012: DVAX submitted the first Heplisov application to the FDA. 2
Slide 34: Current Board Has Not Overseen a Successful Development Pipeline
Current Board Has Not O A ful Devel it Pipeline Two pipeline advancement opportunities have flat out failed 9 Cyltmeibtameet 8 @ipgam + May 2024: DVAX received a complete rejection letter for Hepliscy A 24: DVAK received pd + November 2024: Dynavax discontinued the Tdap program decades and has nothi
Slide 35: Heplisav's Unsuccessful Dialysis Indication
Heplisav’s Unsuccessful Dialysis Indication Clinical development towards Heplisay's dialysis indication has been in process for two decades — with nothing to show for it ~20 YEARS Janvary 2006-March 2008: Sofety vs Energix-B | Trial Code DV2- HBV.09. July 2007-August 2008: Safety/Efficacy | Trial Co
Slide 36: Heplisav's Unsuccessful Dialysis Indication (cont.)
Heplisav’s Unsuccessful Dialysis Indication (cont.) Efforts to obtain an approval for Heplisav in the hemodialysis population will continue into a third decade CEN ee Coir ec OA AO SS SENET NIAID thy have to decid fhe detcoae sf for purove So ts really the stp we're going long term, Roy, our underst
Slide 37: Dynavax's Unsuccessful Tdap Program
Dynavax’s Unsuccessful Tdap Program In November 2024, Dynavax announced it discontinued development of Tdap-1018, yet another recent development failure June 2017: DVAX first entered into collaboration agreement with the Serum Institute of India to develop @ Tdap vaccine. 2/4/2021: First participant
Slide 38: Shingles Program: High Hurdle, Uncertain Success, Low Payoff
Program: High Hurdle, Uncertain Success, Low Payoff [Dvaxelaim There is significant opportunity for DVAX’s shingles vaccine cei, Eact: Competitor Shingrix’s efficacy is nearly perfect, creating an incredibly high hurdle vvory high efficacy to be able to compete with Shingrix. i 1A cE yen pert Cts So
Slide 39: Shingles Program: High Hurdle, Uncertain Success, Low Payoff (cont.)
hingles Program: High Hurdle, Uncertain Success, Low Payoff (cont.) DVAX claim: There is significant opportunity for DVAX’s shingles vaccine {GSK near-perfect inambent (hing sts on impenibe bor morgnel gin in tolrabilty are fc fo prove ond wen sel shore ly compl + Let Phase 1/Il fini money hes alrea
Slide 40: Plague Vaccine: Zero Cost, Zero Cash-Flow, Zero Upside
e: Zero Cost, Zero Cash-Flow, Zero Upside Gov-Funded Plague Vaci DVAX clai + Development of o plague vaccine, for which there is currently no approved vaccine in the U.S. + Plague vaccine is 0 de-risked result of a multi-year partnership with the U.S. Department of Defense. + There is only one custo
Slide 41: CpG 1018: Right Place, Right Time—Then Gone
CpG 1018 : Right Place, Right Time—Then Gone a |e (acc ~~ an Vaore aot 2020| abortion Snel satied. | VAOOT Cove char ang mae gemta ‘Supply =e ‘ meaningful sales — ¢.9., $2M in 2023) coaton li LOE Ga a Erte . a Eee, S020 rao Eee, ssc covmcn emia sented es Prior to reduction scale up for Mr. Myers: sy
Slide 42: The Board is Doubling Down on Cash
The Board is Doubling Down on Cash + In Merch 2025, DVAX ennounced the exchange of the mejriy oftheir DYNAVAX bridge io Convertible notes due 2036 for new peper due 2030, e coment + There are two gleringly obvious erie! flaws that shoreholders are unable to poses) | BEEK | foray, resol + Unnecessary
Slide 43: Non-Heplisav-Related R&D Costs Have Ballooned
Non-Heplisav-Related R&D Costs Have Ballooned And have yet to translate into shareholder value Vast and growing m Yeor 2021 202220232024 gor Soe fea 13908 ‘ne, oder pee ep tons "tame Heed 713_tos 0 ven 3973, 87% sa 0% ye) on on 5421 sco oo B08 ™ te sn Soe om =e ra an ‘ ‘Anaval R&D expenses 92,228 46
Slide 44: Heplisav Sets the Benchmark — No Rival on the Horizon
Heplisav Sets the Benchmark — No Rival on the Horizon A. Study 1: Seroprotection in Adults 18-55 Years of Age 95:% * Heplioy key competitor (Engers-) hos been onthe mmorket for over three and a half decades end sil Heplisav is faster and better ‘as more people protected in one-third the time lisov p
Slide 45: Change is Needed: Heplisav's Market Share is Already Alarmingly Plateaued
Change is Needed: Heplisav’s Market Share is Already Alarmingly Platea Market share growth has stalled: flat q/q and only +2% y/y for the most recent quarter The plan The reality Hefisay Markt Share (as Rpored by DVAR) ond 3 Share by Que Expanding Market Opportunity Trough 2030 Sienternatt ee OVA) t
Slide 46: Analysts are Concerned About Market Share Growth (or Lack Thereof)
Analysts are Concerned About Market Share Growth (or Lack Thereof) Curious, os looking ot the year 2030 guidance, but what is the ee x E as iust that you've got i to try to fi ind of ether accounts orf there something else to help kind of drive continued ‘morket-shore gains between now and 2030? ‘Mo
Slide 47: The Board's Growing Pressure on Management to Identify Assets
to Identify Assets The Board’s Growing Pressure on Since Scott Myers took over as Chairman in 2021, the Board has increasingly pressured management to grow inorganically has tripled from 5% to 15% over the past four years. + Percentage of management compensation tied to sourcing external opportuni \
Slide 48: The Board's Desire to Diversify INTO Risk is Not in Shareholders' Interest
The Board’s Desire to Diversify INTO Risk is Not in Shareholders’ Interest + DVAX believes the market will grow 10-15% every year. So both those segments, so we've stated that the overall market would be 10% to 15% every year growing. And retail and IDN ‘ere going to be the 2 segments that are going
Slide 49: Urgent Change is Needed Now
Urgent Change is Needed Now If the current Board and its high-risk acquisition strategy is allowed to continue, the potential downside for DVAX shares is significant. We are highly concerned the Board will act out of desperation, spending the Company's cash and increasing future operating expenses t
Slide 50: III. The Case for Change in the DVAX Boardroom
BYNOVAX Ill. The Case for Change in the DVAX Boardroom
Slide 51: Reactive Maneuvers Reveal the DVAX Board is Deeply Entrenched
Reactive Maneuvers Reveal the DVAX Board is Deeply Entrenched (x) Poison pill + Adopted poison pill from expressing adi five days after Deep Track amended our 13D filing to prevent us ~ and ony other potential investors nal conviction about the Company's potenti Reactive share buyback + Announced th
Slide 52: Deep Track's Efforts to Reach a Constructive Solution Have Been Rebuffed
Deep Track’s Efforts to Reach a Constructive Solution Have Been Rebuffed We have attempted to compromise but the Board has not changed its position ~ rem shareholder representative join as a director ing steadfastly opposed to having a + vax : 11, end od it ange for Deep apport 2027 + beep ine-membe
Slide 53: Deep Track's Efforts to Reach a Constructive Solution Have Been Rebuffed (cont.)
Deep Track’s Efforts to Reach a Constructive Solution Have Been Rebuffed (cont.) /e have attempted to compromise but the Board has not changed its position ~ rem shareholder representative join as a director ing steadfastly opposed to having a + Deep Trock prope: Erkmen ond, ‘ebolance the Boord’s cl
Slide 54: DVAX's Board "Refreshment" Swaps One Prior Colleague for Another
DVAX’s Board “Refreshment” Swaps One Prior Colleague for Another DVAX's refreshment appears to be @ box-checking exercise rather than a meaningful governance improvement + Following Deep Track’s public engagement, OVAX enacted @ reactive refreshment to check-the-box for governance. + One of Mr. Myer
Slide 55: Mr. Myers Has a Track Record of Value Destruction and Appears Over-Boarded
Mr. Myers Has a Track Record of Value Destruction and Appears Over-Boarded + Chairman Scott Myers is collecting checks os chairman of three other companies, leaving us deeply concerned that four simultaneous chairmonships have left him stretched too thin. I uma Ei cenvergent ¥ zentalis + Concerningl
Slide 56: Directors Have Overseen TSR Underperformance
1 Directors Have Overseen TSR Underperformance Start Date DYNAVAX NASDAQ Biotech Index Brent July 21, 2020 5% % MacGregor Scott Myers October 21, 2021 43% 3% Chai ofthe Board Lauren February 3, 2025 N/A N/A Silvernail Elaine Sun December 14, 2021 19% 4% PEE CUS thre unten tm ten te tar rch late, 24,
Slide 57: The Current Board's Interests are Not Aligned with Shareholders
The Current Board’s Interests are Not Aligned with Shareholders The current Board owns very few shares of DVAX stock and importantly, not one of the Board members up for election this, year, including the chairman, has purchased a single share of DVAX stock on the open market @e2 FroncisCono Elio Em
Slide 58: We are Seeking to Remove Four Incumbent Directors
We are Seeking to Remove Four Incumbent Directors a — Brent MacGregor Scott Myers Lauren Silvernail Elaine Sun rate See 2020 (Chor Sine 2021 Dre Sen 2025, eat Se 2021 x Presided over -91% TSR as x Presided over 43% TSRas x Added to Board as part of x Member of Audit CEO of Medi Chair of the DVAX Boa
Slide 59: The Board's Disregard for the Truth and Independent Oversight is Clear
The Board’s Disregard for the Truth and Independent Oversight is Clear *+ The Company accused Deep Track no fewer thon 10 times of attempting to toke control of the Board across three public communications. member Board. + This is completely false. Deep Track nominated four director candidates to wh
Slide 60: DVAX's Misrepresentations of Engagement with Deep Track
DVAX’s Misrep! i of with Deep Track DVAX’S MYTH REALITY v int did Deep Track “demond” this it Deep Track X Deep Track “demonded” Dynovox finencing. ‘opportunites such oF monetizing royalties. X Deep Track “demonded” Dynavox Deep Spment efforts” thos at no point indicated otherwise. Dynavox adopted a
Slide 61: IV. Our Solution: Independent and Investor-Aligned Voices in the Boardroom
BYNOVAX IV. Our Solution: Independent and Investor-Aligned Voices in the Boardroom
Slide 62: Deep Track's Nominees are the Right Fit
Deep Track’s Nominees are the Right Fit \ af WY Michael Mullette Donald Santel* ie Me it exectve ies Fon ‘ ceri expo, ol mark indy, woud bring Anderstonding of buiesrists |_| leodehip ond amon cop! _ : sional ens poe companies tv, REFOCUS BEEQGUS seems tr ovart
Slide 63: Our Nominees Have the Experience and Skillsets Critical to the DVAX Board
Our Nominees Have the Experience and Skillsets Critical to the DVAX Board The incumbents claim to have expertise in areas where DVAX has fallen short Brett Jeffrey Michael Donald Brent Scott Lauren Elair Erkman Farrow Mullette Santel_ MacGregor Myers __ Silvernail Sun vovov i? 7? < v v v v Si S 7° <
Slide 64: Deep Track Sees a Path to Meaningful Value Creation
Deep Track Sees a Path to Meaningful Value Creation Reassure shareholders on strategy, deploy cash to repurchases, and produce >20% CAGR! shareholder return through 2030 Ste Pp 9) Step 2: Capital Allocat Step 3: Lower Share Count Committed focus on Heplisav growth Return excess cash to shareholders
Slide 65: Change is Urgently Needed to Refocus Dynavax
Change is Urgently Needed to Refocus Dynavax #1 #2 #3 Heplisav growth is the path to Heplisav is Dynavox's “crown A single misguided acquisition greatest value creation forall ewer” will erode yeors of shareholder DVAX shareholders gains + Heplisov’s key compe! + Growing the market and wos approved
Slide 66: Additional Information
Additional Information Vote the WHITE Proxy Card to Refocus Dynavax PROTECT YOUR INVESTMENT IN DYNAVAX Refocus Dynavax by voting for the election of Deep Track’s highly qualified director candidates — Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel — on the WHITE proxy card Please v
Slide 67: V. Appendix
BYNOVAX V. Appendix
Slide 68: Brett Erkman
Brett Erkman REFOCUS DYNOVAX AS ei oa fa nina heat nay ig tn heat, perspec the value of ¥v, dating back to Deep Track’s first investment ignificant investment experience in biotechnology companies. Since October 2022, Brett Erkman hos served as a Menaging Director of Deep Track Copital. Prior 10 Dee
Slide 69: Jeffrey Farrow
Jeffrey Farrow REFOCUS DYNOVAX Me. Farrow’ significant healthear r Perapctive tothe Company cluding as a chief financial officer in the incial background, 19 substantial financi fe and an experienced Jeffrey Farrow hos served as Chief Financial Officer and Chief Strategy Officer of Tarsus rarmeceuti
Slide 70: Michael Mullette
Michael Mullette REFOCUS DYNOVAX Mr. Mullette would bring to the Company strong leadership and day-to-day operational experience, and a deep understanding of business risks, based on his leadership positions in the healthcare and biotechnology space. Michael Mullette is an experienced drug developme
Slide 71: Donald Santel
Donald Santel REFOCUS DYNOVAX experience managing significant mergers and acquisitions activity. Donate Sante! curently serves as chcrmen of he bocrd of a private botecnelogy company, Tentarix Biotherapeutics, since March san independent director of private Biotechnology company, Inogroft Sioerapeue
Slide 72: High-Profile Failures in the Vaccine Space
High-Profile Failures in the Vaccine Space Even if Dynavax does find an asset to acquire, success is by no means guaranteed: JNJ/Senofi EXPECOV E.coli Feiled vs. placebo in Phase 3 - February 13, 2025 HUVX HIL-214 Norovirus Foiled vs. placebo in Phase 2 — June 8, 2024 BAVA.DC MVA-BN RSV Feiled vs. p
Slide 73: High-Profile Failures Following Acquisition
High-Profile Failures Following Acquisition Even if Dynavax does find an asset to acquire, success is by no means guaranteed: aay 3.78 Dec 6, 2023 Feiled vs plocebo in two pivotol rel Now 11, 2024 NYO KBP Bio Up10 $1.38 Oc1 16,2023 Ocedurenone Foiled vs. placebo in Phase 3 ~ Jun 26, 2024 MRK Oncolmm
Slide 74: Heplisav Sets the Benchmark — No Rival on the Horizon
Heplisav Sets the Benchmark — No Rival on the Horizon + Heplisov provides protection from hepotitis 8 in at least nine out of ‘every 10 people vaccinated, setting an exceedingly high bar. + Heplisov accomplishes this in just two shots and one month versus three shots and six mé * Mase tal data are f
Slide 75: Dynavax in the Media
Dynavax in the Media US FDA declines expanded use of Dynavax's hepatitis B vaccine on insufficient data J BioSpace’ FDA Rejects Dynavax's Bid to Expand Use of Hepatitis B Vaccine HCP.i. FDA Issues CRL for HEPLISAV-B in Adults on Her is MARKETS INSIDER Dynavax downgraded to Sell from Neutral at Goldm
Slide 76: Quote from 2024 JP Morgan Healthcare Conference
Quote from 2024 JP Morgan Healthcare Conference (emphasis added) Unknown Analyst Thank you. And then finally from my end, I’m wondering about your capital allocation strategy. What are your priorities there? Kelly MacDonald Dynavax Technologies Corporation – Senior VP & CFO Take that. So, first and
Slide 77: Quote from 2024 JP Morgan Healthcare Conference (emphasis added)
Quote from 2024 JP Morgan Healthcare Conference (emphasis added) Unknown Anslst Kelly MacBoneld 00% Tosi Coxporoon~ Sein VP 8 CFO REFOCUS DYNOVAX
Slide 78: Item 3: On May 6, 2025, Deep Track posted the following materials to the Website
Item 3: On May 6, 2025, Deep Track posted the following materials to the Website. From time to time, Deep Track and the other Participants may refer stockholders of the Company to such materials.
Slide 79: Privacy Policy & Terms of Use
/ PRIVACY POLICY & TERMS ORUSE / REFOCUS. DYNVAX
Slide 80: Deep Track Capital
BYNOVAX / DEEP,TRACK CAPITAL / Deep Track Copitalis the largest of Bifvex Technol with proximately f the Company's outstar nearly 15 years 9go to support the development of Helin oop Track has continue to steadily build our position n the Compony ond purchased shares every quarter from Q4 2022 throu
Slide 81: Disclaimer
7 DISCLAIMER / SEo9eoosooooooos: peooeooes {We WANT 70 HEAR FROM YOUL REFQCUS, DYN@VAX
Slide 82: It's Time for Dynavax to Refocus
IT’S TIME FOR DYN TO REFOCUS. Objective, mestoratgnedperipecivs re naaded nthe ‘cen toinaepeesery eran cbt erly gah ace egw for
Slide 83: How to Vote